We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. The Administrator of personal data is STOCKTRADEIQ sp. z o.o., with its registered office in Poznan (61-625), at the following address: Czarna Rola 30 Street. Cookies policy here. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

  • Cookie
    cookieyes-consent
  • Duration
    1 year
  • Description
    CookieYes sets this cookie to remember users' consent preferences so that their preferences are respected on their subsequent visits to this site. It does not collect or store any personal information of the site visitors.
  • Cookie
    x-ms-cpim-csrf
  • Duration
    session
  • Description

    Inter-site request forgery token used to protect crSF. For more information, read the section Token falsification of requests between sites.

  • Cookie
    x-ms-cpim-sso:stocktradeiqauth.onmicrosoft.com_0
  • Duration
    session
  • Description

    Used to support single sign-on sessions. This cookie is set as persistent when the Keep me logged in option is enabled.

  • Cookie
    server-telemetry-{id}
  • Duration
    persistent
  • Description

    A value used by Microsoft for authorisation and authentication.

  • Cookie
    google_auto_fc_cmp_setting
  • Duration
    persistent
  • Description


    Stores the state of the User cookie for the current domain.

     

  • Cookie
    {id}-https://stocktradeiqauth.onmicrosoft.com/{id}
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    msal{id}.active-account
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-refreshtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-idtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    Microsoft Clarity
  • Duration
    1 year
  • Description

    Microsoft Clarity

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

  • Cookie
    isLightMode
  • Duration
    1 year
  • Description

    Defines the UI theme

  • Cookie
    userCultureData
  • Duration
    persistent
  • Description

     Stores information about the user's machine culture.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

  • Cookie
    _ga
  • Duration
    1 year 1 month 4 days
  • Description
    The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
  • Cookie
    _ga_*
  • Duration
    1 year 1 month 4 days
  • Description
    Google Analytics sets this cookie to store and count page views.
  • Cookie
    hotjar
  • Duration
    1 year 1 month 4 days
  • Description

    Analyzing users' behaviour in the website

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

  • Cookie
    __gpi
  • Duration
    1 year 24 days
  • Description
    Google Ads Service uses this cookie to collect information about from multiple websites for retargeting ads.
  • Cookie
    __gads
  • Duration
    1 year 24 days
  • Description

    The file, set by Google, is stored in the DoubleClick domain and tracks the number of times users view an ad, measures the success of the campaign and calculates its revenue. This cookie can only be read from the domain where it is set and does not track any data when browsing other sites.

  • Cookie
    goog:cached:topics
  • Duration
    persistent
  • Description

    It is used to record which adverts have been displayed to the User.

  • Cookie
    IDE
  • Duration
    year
  • Description

    Used by Google DoubleClick to record and report on the Website User's actions after viewing or clicking on an advertiser's ads in order to measure the effectiveness of the ad and present the User with targeted advertising.

  • Cookie
    google_experiment_mod44
  • Duration
    persistent
  • Description

    Used by Google Ad to experiment with the effectiveness of ads on websites using their services.

Powered by Cookieyes logo

    Get Diamond plan for FREE

    logo

    Exelixis, Inc. (EXEL)

    Price:

    38.63 USD

    ( - -0.08 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    EXEL
    Name
    Exelixis, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    38.630
    Market Cap
    10.399B
    Enterprise value
    9.928B
    Currency
    USD
    Ceo
    Michael M. Morrissey
    Full Time Employees
    1147
    Website
    exelixis.com
    Ipo Date
    2000-04-17
    City
    Alameda
    Address
    1851 Harbor Bay Parkway

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Incyte Corporation

    VALUE SCORE:

    10

    Symbol
    INCY
    Market Cap
    16.606B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    99.056B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Agios Pharmaceuticals, Inc.

    VALUE SCORE:

    12

    Symbol
    AGIO
    Market Cap
    2.254B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    17.483
    P/S
    4.663
    P/B
    5.178
    Debt/Equity
    0.088
    EV/FCF
    14.006
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    4.703
    Earnings yield
    0.057
    Debt/assets
    0.067
    FUNDAMENTALS
    Net debt/ebidta
    0.112
    Interest coverage
    0
    Research And Developement To Revenue
    0.396
    Intangile to total assets
    0.024
    Capex to operating cash flow
    0.030
    Capex to revenue
    0.010
    Capex to depreciation
    0.778
    Return on tangible assets
    0.230
    Debt to market cap
    0.017
    Piotroski Score
    6.000
    FUNDAMENTALS
    PEG
    -3.916
    P/CF
    13.639
    P/FCF
    13.887
    RoA %
    22.490
    RoIC %
    23.200
    Gross Profit Margin %
    96.595
    Quick Ratio
    3.443
    Current Ratio
    3.513
    Net Profit Margin %
    27.009
    Net-Net
    1.423
    FUNDAMENTALS PER SHARE
    FCF per share
    2.747
    Revenue per share
    8.181
    Net income per share
    2.210
    Operating cash flow per share
    2.832
    Free cash flow per share
    2.747
    Cash per share
    2.902
    Book value per share
    7.460
    Tangible book value per share
    7.227
    Shareholders equity per share
    7.460
    Interest debt per share
    0.660
    TECHNICAL
    52 weeks high
    49.620
    52 weeks low
    25.120
    Current trading session High
    38.850
    Current trading session Low
    38.309
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    19.445
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -23.732
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    17.063
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    18.930
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -34.193
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    27.883
    DESCRIPTION

    Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

    NEWS
    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-exelixis-20250822.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

    prnewswire.com

    2025-08-22 10:00:00

    NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investorsofexelixis-20250821.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

    globenewswire.com

    2025-08-21 14:18:00

    NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/will-exels-share-repurchase-program-boost-value-for-investors-20250819.jpg
    Will EXEL's Share Repurchase Program Boost Value for Investors?

    zacks.com

    2025-08-19 10:36:14

    Exelixis repurchases shares for $796M, aiming to boost EPS and shareholder value through 2025.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investorsofexelixis-20250817.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

    globenewswire.com

    2025-08-17 11:04:00

    NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-exelixis-20250816.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

    prnewswire.com

    2025-08-16 10:00:00

    NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/exelixis-gains-156-ytd-how-should-you-play-the-20250814.jpg
    Exelixis Gains 15.6% YTD: How Should You Play the Stock?

    zacks.com

    2025-08-14 10:16:27

    EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-20250813.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

    globenewswire.com

    2025-08-13 11:04:00

    NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/will-zanzalintinib-ease-out-exels-reliance-on-cabometyx-for-20250813.jpg
    Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?

    zacks.com

    2025-08-13 09:55:15

    Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-exelixis-20250811.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

    prnewswire.com

    2025-08-11 10:00:00

    NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investorsofexelixis-20250809.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL

    globenewswire.com

    2025-08-09 11:40:00

    NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-exelixis-inc-20250806.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

    prnewswire.com

    2025-08-06 18:40:00

    NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-exelixis-20250806.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

    prnewswire.com

    2025-08-06 10:30:00

    NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/cabometyx-sales-miss-mark-in-q2-what-does-this-20250805.jpg
    Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?

    zacks.com

    2025-08-05 10:11:13

    EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.

    https://images.financialmodelingprep.com/news/dont-overlook-exelixis-exel-international-revenue-trends-while-assessing-20250804.jpg
    Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock

    zacks.com

    2025-08-04 10:17:03

    Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-exelixis-20250731.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

    prnewswire.com

    2025-07-31 18:45:00

    NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/exelixis-zanzalintinib-sees-mixed-progress-cabozantinib-grinds-upwards-20250731.jpg
    Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards

    seekingalpha.com

    2025-07-31 12:27:25

    EXEL continues to grow cabozantinib revenues while advancing zanzalintinib, but recent trial updates have been mixed and market reaction muted. STELLAR-303 has produced a success for zanzalintinib although the size of the clinical benefit isn't known yet. Zanzalintinib doesn't seem to have outperformed in head and neck cancer, with the company curtailing development in that indication following phase 2 data from STELLAR-305.